Investing.com - Financial Markets Worldwide
⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

BRIEF-Synergy Pharmaceuticals Says Bausch Health To Acquire Its Business Assets

Published 2018-12-12, 06:05 a/m
© Reuters. BRIEF-Synergy Pharmaceuticals Says Bausch Health To Acquire Its Business Assets
SGYPQ
-

Dec 12 (Reuters) - Synergy Pharmaceuticals Inc SGYP.O :

* SYNERGY PHARMACEUTICALS ANNOUNCES AGREEMENT FOR BAUSCH HEALTH TO ACQUIRE ITS BUSINESS ASSETS

* SYNERGY PHARMACEUTICALS INC - DEAL FOR $200 MILLION IN CASH

* SYNERGY PHARMACEUTICALS INC - SYNERGY INITIATED VOLUNTARY PROCEEDINGS UNDER CHAPTER 11 OF U.S. BANKRUPTCY CODE

* SYNERGY PHARMACEUTICALS INC - FULLY INTENDS TO OPERATE ITS BUSINESS AS USUAL WHILE IT WORKS TO COMPLETE SALE THROUGH CHAPTER 11 PROCESS.

* SYNERGY PHARMACEUTICALS INC - BAUSCH HEALTH WOULD ACQUIRE SUBSTANTIALLY ALL OF SYNERGY'S ASSETS, INCLUDING ALL RIGHTS TO TRULANCE, DOLCANATIDE

* SYNERGY PHARMACEUTICAL - ENTERED BINDING TERM SHEET WITH EXISTING FIRST LIEN LENDERS FOR DIP FINANCING IN AMOUNT EQUAL TO $155 MILLION

* SYNERGY PHARMACEUTICALS - DIP FINANCING IS COMPRISED OF $110 MILLION OF ROLL UP PRE-PETITION LOAN OBLIGATIONS AND $45 MILLION OF NEW MONEY LOANS

* SYNERGY PHARMACEUTICALS - ALSO HAS FILED CUSTOMARY MOTIONS WITH COURT SEEKING AUTHORIZATION TO CONTINUE EMPLOYEE WAGES AND BENEFIT PROGRAMS, OTHERS

* SYNERGY PHARMACEUTICALS INC - SYNERGY AND ITS ADVISORS WILL EVALUATE COMPETING BIDS THAT MAY BE SUBMITTED

* SYNERGY PHARMACEUTICALS - PROPOSED SALE TO BAUSCH HEALTH IS EXPECTED TO BE CONDUCTED THROUGH SUPERVISED SALE PROCESS UNDER BANKRUPTCY CODE

* SYNERGY PHARMACEUTICALS INC - AGREEMENT WITH BAUSCH HEALTH COMPRISES INITIAL STALKING HORSE BID IN COURT-SUPERVISED AUCTION PROCESS

Latest comments

Loading next article…
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.